Leaders in next-generation targeted protein degrader design and development

Biotheryx is advancing a portfolio of first-in-class protein degraders, with an initial focus on validated targets in cancer and inflammatory disease.

Uniquely modulating Cereblon to control its function in ways no-one has ever done before

Our PRODEGY (Protein Degrader Technology) platform was designed as a new and powerful targeted protein degradation drug discovery engine. Our platform was built on our expertise in modulating Cereblon and includes proprietary solutions and unique tools for targeted protein degrader (TPD) drug design.

A pipeline of first-in-class protein degraders with potential to transform patient treatment.

Leveraging our PRODEGY platform, we are building a pipeline of first-in-class protein degraders, including molecular glues and bifunctional degraders, with an initial focus in oncology and inflammatory disorders.

Biotheryx is a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders, including bifunctional degraders and molecular glues. Our focus is deploying the differentiated potential of degraders towards validated targets in cancer and inflammatory disease. Members of our founding and scientific teams previously developed the first U.S. Food and Drug Administration (FDA) approved modulators of Cereblon, the most widely validated E3 ligase involved in protein degradation, and we have applied our expertise in Cereblon binding to build our proprietary PRODEGY platform.

We are a purpose-driven team, passionate about leveraging our PRODEGY platform to discover and develop targeted protein degraders to address severe unmet patient needs. In doing so, we seek to build Biotheryx into a leader in next-generation targeted protein degradation.